SOUTHERN MEDICAL SCIENCE CO., LTD.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
Development of an Automated Instrument for the Isolation of Adipose-Derived Stem Cells (ADSCs)
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2017
Unified Business No.
59249323
Status
Closed
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
SOUTHERN MEDICAL SCIENCE CO., LTD. is dedicated to the application of animal and human adipose-derived mesenchymal stem cells, and provides high-quality services including pet adipose-derived mesenchymal stem cell services. SOUTHERN MEDICAL SCIENCE CO., LTD. aims to research, develop, manufacture, and market a machine that isolates and purifies adipose-derived mesenchymal stem cells (ADSCs) within a short timeframe (approximately 1.5 hours) to meet the scheduling demands of general surgery. This brand-new medical device effectively isolates and screens a sufficient quantity of ADSCs from subcutaneous fat through a sterile process in the operating room for tissue reconstruction in regenerative medicine. The advantage of this adipose-derived mesenchymal stem cell isolation machine lies in its ability to rapidly, stably, and efficiently isolate stem cells, allowing individuals to use their own stem cells for tissue reconstruction. Following its establishment, the company will prioritize pet therapy, providing rapid autologous isolation as well as allogeneic adipose-derived mesenchymal stem cells. In the field of human regenerative medicine, the company aims to obtain medical device regulatory certifications in various countries in the future, with the expectation of applying this technology to human regenerative medicine worldwide.
(The content above was translated by AI.)
(The content above was translated by AI.)
